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BACKGROUND  
In recent years, various injectable materials have come into use to improve esthetic 
appearance. 
 
OBJECTIVE 
We describe the clinical and histopathologic aspects of two patients who received 
intradermal injections of an unknown dermal filler and the different diagnostic tools 
used to identify the unknown injected material (reflexion electron microscopy, electron 
dispersing x-ray) and discuss the possibility of a metastatic granulomatous reaction in 
one patient. We also describe two treatments for this complication and evaluate the legal 
considerations of the use of materials that have been adulterated and/or whose 
composition is unknown to the patient. 
 
METHODS 
We present two patients who developed a granulomatous foreign-body reaction after the 
subcutaneous injection of an esthetic implant. We treated patient 1 with isotretinoin and 
2 months later with doxycycline. We administered isotretinoin to patient 2. 
RESULTS. We observed a partial improvement in patient 1 after isotretinoin treatment 
and a remarkable improvement after administration of doxycycline. In patient 2, we 
observed an excellent response to isotretinoin. 
 
CONCLUSION 
Isotretinoin and doxycycline, when administered separately, seem to offer effective 
treatment for reactions resulting from silicone implants. However, further studies that 
include a larger number of patients and those with reactions secondary to other fillers 
are clearly needed before the effectiveness of this treatment can be confirmed. 
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Over the last few years, various materials have been used to improve esthetic 
appearance, including silicone, ethylmethacrylate, hyaluronic acid (eg, Dermalive), 
polymethylmethacrylate microspheres in partly denatured bovine collagen (eg, 
Artecoll), and others. These materials are usually well tolerated, but secondary local 
effects have been reported, mainly after using silicone. In addition, the possible 
induction of autoimmune diseases still remains controversial. We present two patients 
who developed a granulomatous foreign-body reaction after the subcutaneous injection 
of an esthetic implant in another medical center. We describe the clinical and 
histopathologic aspects and discuss the possibility of a metastatic granulomatous 
reaction in one patient, as well as the different diagnostic tools used to identify the 
unknown injected material. We evaluate the medical consequences of these injections, 
the different therapeutic approaches possible, and the legal considerations secondary to 
the use of materials that have been adulterated and/or whose composition is unknown to 
the patient. 
 
 
 
CASE REPORTS  
 
Case 1 
A 68-year-old woman presented at our hospital with a 2-year history of perioral 
cutaneous induration and visible hypertrophy in this area. Approximately 5 years 
earlier, she had received subcutaneous injections of an unknown material in the labial 
folds in another hospital. In the last 2 years, the inflammation had been progressive, 
spreading to both cheeks and the perinasal area. The patient had been treated in other 
hospitals with deflazacort, methylprednisolone, betamethasone, and ceftriaxone, without 
any improvement. Clinical examination revealed violet patched perioral lesions with 
diffuse margins, pronounced hypertrophy, intense labial edema restricting mouth 
opening, and palpable skin induration in the perioral and cheek area (Figure 1A). A 
cutaneous biopsy specimen was obtained. Histologic examination showed a dense 
chronic inflammatory granulomatous infiltrate in the dermis and between striated 
muscle fibers, where multinucleated giant cells suggestive of foreign-body reaction 
were identified. Inside some giant cells, vacuoles were recognizable (Figure 1B), but no 
birefringent material was observed. The bacteriologic and mycologic cultures and Ziehl-
Neelsen staining from the skin specimen were negative. A reflexion electron 
microscopy (REM) probe demonstrated the presence of particles of material within the 
granuloma (Figure 1C), and electron dispersing x-ray (EDX) (Figure 1D) revealed high 
levels of silica, suggesting the existence of silicone. Cranial computed tomography was 
performed and revealed a diffuse reaction with vague margins, extending from the 
mandibular symphysis to the base of the nasal pyramid, involving the upper and lower 
lips (Figure 1E). Blood cell count and hepatic enzymes revealed no abnormal levels. 
The antinuclear antibody titer was 1/40. She was typed for HLA antigens and was found 
positive for A24, B44, CW4, DR4, DR52, DRB4, B35, BW4, BW6, and DR7. We 
started treatment with isotretinoin (0.5 mg/kg/d for 6 months), combined with 
prednisone (20 mg for 1 week, and then the dose was gradually tapered), only for the 
first month of treatment. An improvement in inflammation, induration, and mouth 
opening was observed (Figure 1F). Two months after discontinuation of isotretinoin, 
doxycycline (100 mg/bid) was administered for 2 months, with further improvement. 
 
 
Case 2 
A 65-year-old woman presented with a 2-year history of painful interciliary and 
supralabial induration. Two years before presentation, an unknown material had been 
injected subcutaneously at another medical center. She denied arthralgias, 
photosensitivity, or any other health problems. Intralesional corticosteroids had been 
infiltrated in another center, but a peripheral spread of the granuloma occurred. Physical 
examination revealed perioral edema and subcutaneous interciliary induration, 3 cm in 
diameter (Figure 2A), also in the left supraorbital area. An induration, 2.5 cm in width, 
was palpable close to the lower lip and chin and extended to both corners of the mouth. 
Histologic examination revealed granulomas and vacuoles inside giant cells (Figure 
2B). REM showed particles of material within the granuloma (Figure 2C), and EDX 
analysis demonstrated the presence of silicone. The antinuclear antibody titer was 1/80. 
Expression of HLA antigens A11, B27, B35, BW4, BW6, DR7, DRW53, and DQ2 was 
found. Computed tomography demonstrated deposition of a subdermal substance 
without bone involvement (Figure 2D). After treatment with isotretinoin (0.5 mg/kg/d 
for 6 months), the indurated lesions disappeared (Figure 2E). Interestingly, although the 
patient developed no new facial lesions, 6 months after discontinuation of the treatment, 
some violet asymptomatic infiltrated lesions appeared on her lumbar area. Clinical 
examination revealed erythematoviolaceous plaques, ranging from 1 to 4 cm in 
diameter, on her lumbar area (Figure 2F) and enlargement of a laparotomy scar. Cell 
blood count and serum angiotensin-converting enzyme levels were in the normal range. 
Chest radiography revealed no alterations indicating pulmonary sarcoidosis. Histologic 
examination demonstrated a granulomatous foreign-body reaction, with vacuoles inside 
giant cells, compatible with distant spread of silicone (Figure 2G). Examination with 
EDX could not confirm the existence of silicone in this area. 
 
 
 
DISCUSSION 
 
Reports of granulomatous reactions secondary to substances used as esthetic implants 
are not infrequent. Sometimes, the patient is not informed about the material injected, 
and the identification and subsequent treatment are correspondingly difficult. Recently, 
Requena and colleagues established distinctive morphologic findings for each type of 
microimplant,1 which may be useful in distinguishing between the substances used. 
Thus, silicone granulomas show intracellular and extracellular nonbirefringent vacuoles, 
whereas Artecoll (polymethylmethacrylate microspheres in partly denatured 3.5% 
bovine colla-gen) and Dermalive (hyaluronic acid with acrylic hydrogel) present only 
extracellular vacuoles. On the basis of these descriptions, the injected material in our 
patients may be silicone because we observed intracellular vacuoles in both biopsies. 
The histologic findings in our patients are characteristic of a foreign-body 
granulomatous reaction. However, histology is not accurate enough to identify these 
materials. REM and EDX seem to be useful diagnostic tools for identifying occult 
materials.2 These techniques point toward the presence of silicone in a cutaneous 
biopsy, as occurred in the probes we analyzed. 
In our opinion, the correct management of these patients (Table 1) may consist of a 
physical examination and a laboratory analysis targeted to rule out an associated 
autoimmune disease. A skin biopsy must be performed, and it should be cultured and 
subjected to histologic examination and, if possible, to REM and EDX. Moreover, a 
radiographic study should be performed to exclude soft tissue and bone inflammation. 
The association between silicone and connective tissue diseases is controversial. The 
National Academy of Science (United States)3 and the Medical Device Agency (United 
Kingdom) concluded that there is not sufficient evidence to confirm this association.4 In 
the patients in our study, we found few clinical and laboratory data suggestive of an 
immunologic reaction. We observed low antinuclear antibody titers of 1/40 and 1/80, 
respectively, and a granulomatous distant reaction in patient 2. The pathophysiology of 
these reactions is controversial. The infiltrate of macrophages, lymphocytes, and giant 
cells has been suggested as occurring secondary to a cellular immunity phenomenon.5 
An immune mechanism is also supposed in positive skin testings with hyaluronic acid 
performed in patients who developed skin reactions secondary to hyaluronic acid skin 
fillers.6 The observation of plasmatic cells suggests a humoral response, but no specific 
antibodies against silicone have been found.4,7 Silicone may also interact with serum 
proteins and act as an antigenic haptin stimulating inflammation.8,9 Moreover, HLA 
antigens may also play a role in granulomatous reactions. Thus, some HLA antigens 
have been found with an increased frequency in annular granuloma, sarcoidosis, and 
other granulomatous diseases.10,11 Interestingly, our two patients share common HLA 
antigens (B35, BW4, BW6, DR7). One of them, HLAB35, has also been described in 
annular granuloma,9 whereas HLA antigens DR5 and DR52, present in patient 1, have 
also been observed in sarcoidosis.12
Several granulomatous reactions have been described after using medical and 
nonmedical-grade silicone.13–15 From the beginning of the medical use of this substance 
in 1940, local and distant complications have been observed,16,17 probably related to its 
ability to migrate through subcutaneous planes18 and to the lymph nodes.19 Although 
injected silicone was thought to be inert and safe, toxicity studies in animals have 
demonstrated that systemic administration of silicone is able to induce acute pulmonary 
edema, pneumonia, hepatic fibrosis, and death secondary to embolism.20–22 The 
injection of silicone in humans has been reported to induce local erythema, ecchymosis, 
ulceration,23 hyperpigmentation, or granulo-mas. Furthermore, even blindness has been 
described after injections close to the ophthalmic vessels.24 According to the literature, 
the incidence of granulomatous reactions is variable. Some authors have found these 
reactions in 13 of 92 patients injected,13 whereas others have reported no cases after 
17,000 injections.25 Possible explanations for these disparities in incidence include the 
quantity of silicone injected, the presence of contaminants, and the depth of injection. 
Silicone implants have also been used in breast augmentation and have been found to 
cause arthritis, renal failure, scleroderma, and eosinophilic fasciitis,13,14,25–27 probably 
owing to an autoimmune reaction, although some recent reviews have questioned these 
findings.4 Recently, Suzuki and colleagues described a metastatic silicone granuloma 
and sicca complex in a silicone breast implant recipient.16 In our study, the presence of a 
granulomatous distant lesion with intracellular vacuoles in patient 2 points to the 
physical distant presence of silicone and not a systemic immune reaction to the esthetic 
implant. This distant presence is compatible with the ability of silicone to migrate 
through the lymph nodes or subcutaneous planes, as has been already described.18,19
Our patients did not respond to previous treatment with intralesional cortiicosteroids, 
which is one of the firstline treatment options (see Table 1). Other treatments that have 
been described include allopurinol,28 surgical excision, and immunomodulating agents 
(oral, intramuscular, intravenous, imiquimod).29 Jansen and colleagues described a 
patient with a granulomatous reaction to silicone that improved after the administration 
of isotretinoin, probably as a result of the anti-inflammatory effect described by Plewig 
and Wagner.2,30 In our study, we observed an evident improvement in patient 2 when 
treated with isotretinoin. Other authors have found that this drug is effective in other 
granulomatous diseases, such as actinic granuloma and granulomatous rosacea,11,31 in 
which exaggerated inflammation occurs. Furthermore, we observed a partial 
improvement in patient 1 after treatment with isotretinoin and a remarkable 
improvement after administration of doxycycline. We decided to administer 
doxycycline following the report of a clinical antiinflammatory response with 
tetracyclines in other granulomatous diseases, such as sarcoidosis.32
In view of the increasing use of esthetic implants, we will witness a rise in the incidence 
of reactions secondary to these injections. From a legal point of view, the injection of 
these materials must be approved (ie, in Spain, as in some other countries, the injection 
of silicone is forbidden), and the patient must provide written informed consent and 
must be informed of the exact composition and quantity of the material being injected. 
These data should be clearly noted in the patient’s medical record. 
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Figure 1. Patient 1: (A) Clinical picture before treatment: pronounced hypertrophy and 
intense labial edema; (B) histologic examination (hematoxylin-eosin stain; x400 
original magnification): vacuoles inside giant cells; (C) reflexion electron microscopy: 
presence of particles of material within the granuloma; (D) electron dispersing x-ray: 
high presence of silica, suggesting the presence of silicone; (E) cranial computed 
tomography: diffuse reaction from the mandibular symphysis to the base of the nasal 
pyramid; (F) clinical picture after treatment: improvement in inflammation, mouth 
opening, and induration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Patient 2: (a) clinical picture before treatment: interciliary, left supraorbital, 
lower lip, and chin subcutaneous induration; (b) histologic examination (hematoxylin-
eosin stain; x 400 original magnification): granuloma and vacuoles inside giant cells; (c) 
reflexion electron microscopy: particles of material within the granuloma (arrows); (d) 
computed tomography: subdermal deposition without bone involvement; (e) clinical 
picture after treatment: indurated lesions have disappeared; (f) picture of the lumbar 
area (6 months after discontinuation of the treatment): violet asymptomatic infiltrated 
lesions; (g) histologic examination of lumbar lesions (hematoxylin-eosin stain; x 200 
original magnification): granulomas with vacuoles inside giant cells. 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Management of patients with adverse rReaction to esthetic implants 
(Presumably silicone) 
History: injected substance, volume, evolution of the disease 
Physical examination: rheumatoid manifestations 
Analysis: ANA, ENA, ACE 
Radiographic studies: CT and/or MRI 
Histology: intra- and extracellular inclusions 
Skin culture: fungal, mycobacteria 
Determination of the injected material: electron dispersing x-ray and reflexion 
electron microscopy 
Treatment options: 
- Local: corticosteroids: topical or intralesional 
Topical imiquimod29
- Systemic: systemic corticosteroids 
Systemic allopurinol28
Prednisone (0.3–05 mg/kg/d) 1 mo together with isotretinoin (0.5 mg/kg/d 5 
mo); if refractable: doxycycline 100 mg/bid 3 mo 
Immunomodulating agents29
- Surgery: surgical excision 
ACE = angiotensin-converting enzyme; ANA = antinuclear antibodies; CT = computed 
tomography; ENA = antibodies to extractable nuclear antigens; MRI = magnetic 
resonance imaging. 
